"One of the nation's premier plaintiffs' firms."
"Representing the best qualities of the plaintiffs' bar."
The National Law Journal
"Their effective and caring advocacy for clients has earned Lieff Cabraser its first-class reputation."
The Daily Journal
Donald Arbitblit To Speak On New Research Concerning Risks of Yaz and Yasmin
November 7, 2011
The American Association for Justice will be holding a teleseminar on November 10, 2011 on Yaz and Yasmin litigation, in response to a new FDA -sponsored study released on October 27, 2011, finding that women taking Yasmin had a 75 percent greater chance of developing a dangerous blood clot than women taking older birth control drugs.
During the teleseminar, Lieff Cabraser attorney Donald C. Arbitblit will discuss the FDA study and another recently published article that found that both Yaz and Yasmin doubled the risk of blood clots compared to earlier generation oral contraceptives among Danish women.